[
  {
    "condition": "Acute Myocardial Infarction",
    "guideline_title": "2023 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization",
    "organization": "American College of Cardiology/American Heart Association",
    "year": 2023,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "Primary PCI is recommended for patients with STEMI presenting within 12 hours of symptom onset",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for 12 months unless contraindicated",
        "evidence": "Meta-analysis of randomized trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "High-intensity statin therapy should be initiated in all patients with ACS",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "B",
        "recommendation": "Beta-blocker therapy should be initiated within 24 hours in patients without contraindications",
        "evidence": "Meta-analysis of randomized trials"
      }
    ],
    "diagnostic_criteria": [
      "Chest pain or equivalent symptoms",
      "ECG changes (ST elevation, new LBBB, or ST depression)",
      "Elevated cardiac biomarkers (troponin)",
      "Imaging evidence of new loss of viable myocardium"
    ],
    "treatment_protocol": [
      "Immediate assessment and triage",
      "ECG within 10 minutes",
      "Aspirin 325mg chewed",
      "Primary PCI if available within 90 minutes",
      "Thrombolytic therapy if PCI not available",
      "Dual antiplatelet therapy",
      "Statin therapy",
      "ACE inhibitor or ARB",
      "Beta-blocker if no contraindications"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "2023 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization",
        "journal": "Journal of the American College of Cardiology",
        "year": 2023,
        "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063"
      }
    ]
  },
  {
    "condition": "Sepsis",
    "guideline_title": "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021",
    "organization": "Society of Critical Care Medicine",
    "year": 2021,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "Administer antimicrobials within 1 hour of recognition of sepsis or septic shock",
        "evidence": "Multiple observational studies"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Obtain blood cultures before antimicrobial administration if possible",
        "evidence": "Observational studies"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Administer 30mL/kg crystalloid for hypotension or lactate ≥4mmol/L",
        "evidence": "Randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Use norepinephrine as first-line vasopressor",
        "evidence": "Multiple randomized controlled trials"
      }
    ],
    "diagnostic_criteria": [
      "Suspected or confirmed infection",
      "SOFA score ≥2 points",
      "qSOFA score ≥2 points (systolic BP ≤100mmHg, respiratory rate ≥22/min, altered mental status)"
    ],
    "treatment_protocol": [
      "Sepsis-6 bundle implementation",
      "Blood cultures before antibiotics",
      "Lactate measurement",
      "Antibiotics within 1 hour",
      "Fluid resuscitation (30mL/kg crystalloid)",
      "Vasopressors if needed",
      "Source control",
      "Corticosteroids in refractory shock"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021",
        "journal": "Intensive Care Medicine",
        "year": 2021,
        "url": "https://link.springer.com/article/10.1007/s00134-021-06506-y"
      }
    ]
  },
  {
    "condition": "Type 2 Diabetes Mellitus",
    "guideline_title": "Standards of Medical Care in Diabetes—2024",
    "organization": "American Diabetes Association",
    "year": 2024,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "Metformin is the preferred initial pharmacologic agent for type 2 diabetes",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "HbA1c target <7% for most nonpregnant adults",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit in patients with established ASCVD",
        "evidence": "Cardiovascular outcome trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Blood pressure target <130/80 mmHg",
        "evidence": "Multiple randomized controlled trials"
      }
    ],
    "diagnostic_criteria": [
      "HbA1c ≥6.5%",
      "Fasting plasma glucose ≥126 mg/dL",
      "2-hour plasma glucose ≥200 mg/dL during OGTT",
      "Random plasma glucose ≥200 mg/dL with symptoms"
    ],
    "treatment_protocol": [
      "Lifestyle modifications (diet, exercise, weight loss)",
      "Metformin as first-line therapy",
      "Add second agent if HbA1c not at target",
      "Consider GLP-1 RA or SGLT2i for cardiovascular benefit",
      "Insulin therapy if oral agents fail",
      "Regular monitoring of HbA1c, blood pressure, lipids"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "Standards of Medical Care in Diabetes—2024",
        "journal": "Diabetes Care",
        "year": 2024,
        "url": "https://diabetesjournals.org/care/issue/47/Supplement_1"
      }
    ]
  },
  {
    "condition": "Hypertension",
    "guideline_title": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults",
    "organization": "American College of Cardiology/American Heart Association",
    "year": 2017,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "Blood pressure target <130/80 mmHg for most adults",
        "evidence": "SPRINT trial and meta-analyses"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "ACE inhibitors or ARBs as first-line therapy for most patients",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Thiazide-type diuretics as first-line therapy for most patients",
        "evidence": "ALLHAT trial and meta-analyses"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Lifestyle modifications including DASH diet, sodium restriction, and regular exercise",
        "evidence": "Multiple randomized controlled trials"
      }
    ],
    "diagnostic_criteria": [
      "Systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg on multiple occasions",
      "Proper measurement technique with appropriate cuff size",
      "Multiple readings over time to confirm diagnosis"
    ],
    "treatment_protocol": [
      "Lifestyle modifications (DASH diet, sodium <2.3g/day, exercise)",
      "ACE inhibitor or ARB as first-line",
      "Add thiazide diuretic if needed",
      "Add calcium channel blocker if needed",
      "Consider beta-blocker for specific indications",
      "Regular monitoring and follow-up"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults",
        "journal": "Journal of the American College of Cardiology",
        "year": 2017,
        "url": "https://www.ahajournals.com/doi/10.1161/HYP.0000000000000065"
      }
    ]
  },
  {
    "condition": "Heart Failure",
    "guideline_title": "2022 AHA/ACC/HFSA Heart Failure Guideline",
    "organization": "American Heart Association/American College of Cardiology",
    "year": 2022,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "ACE inhibitors or ARBs for patients with HFrEF",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) for patients with HFrEF",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "SGLT2 inhibitors (dapagliflozin, empagliflozin) for patients with HFrEF",
        "evidence": "DAPA-HF and EMPEROR-Reduced trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Aldosterone antagonists (spironolactone, eplerenone) for patients with HFrEF",
        "evidence": "RALES and EMPHASIS-HF trials"
      }
    ],
    "diagnostic_criteria": [
      "Symptoms of heart failure (dyspnea, fatigue, edema)",
      "Evidence of structural or functional cardiac abnormality",
      "Elevated natriuretic peptides (BNP >100 pg/mL or NT-proBNP >300 pg/mL)"
    ],
    "treatment_protocol": [
      "Lifestyle modifications (sodium restriction, fluid restriction, exercise)",
      "ACE inhibitor or ARB",
      "Beta-blocker",
      "SGLT2 inhibitor",
      "Aldosterone antagonist",
      "Diuretics for symptom relief",
      "Regular monitoring and follow-up"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "2022 AHA/ACC/HFSA Heart Failure Guideline",
        "journal": "Journal of the American College of Cardiology",
        "year": 2022,
        "url": "https://www.ahajournals.com/doi/10.1161/CIR.0000000000001063"
      }
    ]
  },
  {
    "condition": "Stroke",
    "guideline_title": "2021 Guidelines for the Early Management of Patients With Acute Ischemic Stroke",
    "organization": "American Heart Association/American Stroke Association",
    "year": 2021,
    "recommendations": [
      {
        "class": "I",
        "level": "A",
        "recommendation": "IV alteplase within 4.5 hours of symptom onset for eligible patients",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Mechanical thrombectomy within 24 hours for large vessel occlusion",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Aspirin 325mg within 24-48 hours for most patients",
        "evidence": "Multiple randomized controlled trials"
      },
      {
        "class": "I",
        "level": "A",
        "recommendation": "Blood pressure management with target <185/110 mmHg for thrombolysis",
        "evidence": "Observational studies and expert consensus"
      }
    ],
    "diagnostic_criteria": [
      "Sudden onset of neurological deficit",
      "CT scan to rule out hemorrhage",
      "NIH Stroke Scale assessment",
      "Time of symptom onset documentation"
    ],
    "treatment_protocol": [
      "Immediate assessment and triage",
      "CT scan within 25 minutes",
      "IV alteplase if eligible within 4.5 hours",
      "Mechanical thrombectomy if large vessel occlusion",
      "Aspirin within 24-48 hours",
      "Blood pressure management",
      "Secondary prevention measures"
    ],
    "sources": [
      {
        "type": "clinical_guideline",
        "title": "2021 Guidelines for the Early Management of Patients With Acute Ischemic Stroke",
        "journal": "Stroke",
        "year": 2021,
        "url": "https://www.ahajournals.com/doi/10.1161/STR.0000000000000375"
      }
    ]
  }
]
